Abbott downsizes vascular biz
This article was originally published in The Gray Sheet
Executive Summary
Abbott says it remains optimistic about prospects for its Xience everolimus-eluting coronary stent and that internal estimates of the device's potential remain unchanged despite plans to cut 1,200 manufacturing jobs from the firm's vascular products business. Initiated Dec. 4, the reductions in force reflect overcapacity due to recent increases in efficiency, as well as market conditions that include a weak U.S. drug-eluting stent sector, the company says. Abbott will close its Galway, Ireland facility with 500 employees and downsize its Temecula, Calif. facility by 700 - going from a total of about 4,700 to 4,000. The action will be completed over the next several months, according to the company. Abbott notes that it remains on track to launch Xience in the United States in the first half of 2008 following an approval recommendation from FDA's Circulatory System Devices Panel Nov. 29; the device has been available in Europe since last fall (1"The Gray Sheet" Dec. 3, 2007, p. 3). Competitors Johnson & Johnson and Boston Scientific also recently initiated downsizing actions encompassing their stent businesses to help address declining sales of the devices (2"The Gray Sheet" Oct. 22, 2007, p. 6)
You may also be interested in...
FDA Advisory Panel Cautiously Endorses Abbott Xience V Drug-Eluting Stent
FDA's Circulatory System Devices panel overwhelmingly endorsed PMA approval of Abbott's Xience V everolimus-eluting, despite reservations about its long-term safety
Boston Scientific Cuts Workforce By 13% To Help Save In ’08 H
Boston Scientific will reduce its head count by 2,300 and consolidate certain business units as part of a broader restructuring plan aimed at saving an estimated $475 million to $525 million in 2008, the firm announced Oct. 17
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.